Acute Myeloid Leukemia
Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Melissa BadamoAcute Myeloid Leukemia | March 1, 2024
The percentage of KMT2A-altered cells decreased from 59.2% to 8.1% after treatment with JNJ-75276617.
Read More
Blood Cancer TalksAcute Myeloid Leukemia | February 13, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Melissa BadamoAcute Myeloid Leukemia | February 8, 2024
Foretinib also showed potent activity against secondary mutations that drive resistance to quizartinib and gilteritinib.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | February 8, 2024
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Melissa BadamoAcute Myeloid Leukemia | February 6, 2024
The combined CR/CRi rate was 96% for the frontline cohort, compared with 27% for the relapsed or refractory cohort.
Melissa BadamoAcute Myeloid Leukemia | February 1, 2024
Researchers from St. Jude Children’s Research Hospital developed SJ3149, a selective and potent degrader of CK1α protein.
Advertisement
Melissa BadamoAcute Myeloid Leukemia | February 8, 2024
Oral decitabine plus cedazuridine is a safe and effective alternative to intravenous decitabine.
Melissa BadamoAcute Myeloid Leukemia | January 22, 2024
Mezigdomide has the greatest capacity to synergize with menin inhibitors and MEN1 mutant models.
Leah SherwoodAcute Myeloid Leukemia | January 5, 2024
The authorization by the European Commission is based on results from the QuANTUM-First trial.
Jerald Radich, MDAcute Myeloid Leukemia | January 17, 2024
"MRD positivity is an indication to go to transplant in these patients,” Dr. Radich said.
Phillip Scheinberg, MDMyelodysplastic Syndromes | December 14, 2023
Dr. Schienberg discussed luspatercept in MDS, selinexor in AML, and the difficulty of randomizing trials.
Ashley Yocum, PhDAcute Myeloid Leukemia | December 14, 2023
The Beat AML study assigns newly diagnosed patients to a biomarker specific treatment.
Gwen Nichols, MDAcute Myeloid Leukemia | December 12, 2023
The goal of PedAL is to establish a data-driven developmental therapeutics program.
Afaf Osman, MDAcute Myeloid Leukemia | December 12, 2023
Dr. Osman discussed menin inhibitors for leukemia, and axatilimab treatment for graft-versus-host disease.
Katie KoskoAcute Myeloid Leukemia | December 11, 2023
Mayo Clinic researchers released the data on relapsed or refractory patients with AML who were a median age of 65 years.
Melissa BadamoMyeloproliferative Neoplasms | December 13, 2023
Tasquinimod inhibited interaction of A9, a protein associated with poor prognosis.
Melissa BadamoMyeloproliferative Neoplasms | December 13, 2023
DT2216 alone was effective, but exhibited a slightly greater cell viability reduction when combined with other therapies.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | December 8, 2023
Dr. Xia Jiang and colleagues collected AML cell lines to test the efficacy of venetoclax with NL-101.
Melissa BadamoAcute Myeloid Leukemia | December 13, 2023
The study tested the combination therapy in a patient-derived xenograft (PDX) model of NPM1-mutated AML.
Leah SherwoodAcute Myeloid Leukemia | December 6, 2023
Overall, significantly higher rates of ≥8-week, ≥24-week, and ≥1-year RBC-TI were achieved in patients receiving ...
Advertisement
Advertisement
Editorial Board